Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.

The firm will test additional doses and use its proprietary drug response predictor to gather data that can inform a registrational study.

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

The biotech has met with UK regulators to discuss a marketing authorization application under exceptional circumstances based on data from 11 patients.

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...

Researchers will launch a randomized clinical trial to assess whether PGx-guided care helps keep patients out of the ER and ...

The registrational trial will include 212 patients who are newly diagnosed with advanced head and neck cancer.

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.

Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.

NEW YORK – Real-world data have illuminated emerging treatment patterns for Novartis' radiopharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in both academic and community oncology ...